CoChat
Sign Up
Cited by 156Maternal Mental Health During Pregnancy and PostpartumTreatment of Major DepressionPregnancy-related medical research

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development

Open access
Frieder, Ariela, Fersh, Madeleine, Hainline, Rachel, Deligiannidis, Kristina M.·2019·CNS Drugs
DOI 10.1007/s40263-019-00605-7PMC PMC6424603
Open this paper in CoChat — free account

Abstract

Postpartum depression is one of the most common complications of childbirth. Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences. There are a number of therapeutic interventions for postpartum depression including pharmacotherapy, psychotherapy, neuromodulation, and hormonal therapy among others, most of which have been adapted from the treatment of major depressive disorder outside of the peripartum period. Current evidence of antidepressant treatment for postpartum depression is limited by the small number of randomized clinical trials, underpowered samples, and the lack of long-term follow-up. The peripartum period is characterized by rapid and significant physiological change in plasma levels of endocrine hormones, peptides, and neuroactive steroids. Evidence supporting the role of neuroactive steroids and γ-aminobutyric acid (GABA) in the pathophysiology of postpartum depression led to the investigation of synthetic neuroactive steroids and their analogs as potential treatment for postpartum depression. Brexanolone, a soluble proprietary intravenous preparation of synthetic allopregnanolone, has been developed. A recent series of open-label and placebo-controlled randomized clinical trials of brexanolone in postpartum depression demonstrated a rapid reduction in depressive symptoms, and has led to the submission for regulatory approval to the US Food and Drug Administration (decision due in March 2019). SAGE-217, an allopregnanolone analog, with oral bioavailability, was recently tested in a randomized, double-blind, placebo-controlled phase III study in severe postpartum depression, with reportedly positive results. Finally, a 3β-methylated synthetic analog of allopregnanolone, ganaxolone, is being tested in both intravenous and oral forms, in randomized, double-blind, placebo-controlled phase II studies in severe postpartum depression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-019-00605-7

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 182

  1. [1]Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries. Frontiers in psychiatry. 2017; 8: 248. doi: 10.3389/fpsyt.2017.00248. 29449816 PMC5799244 · DOI · Paper page
  2. [4]Madigan S, Oatley H, Racine N, Fearon RMP, Schumacher L, Akbari E A Meta-Analysis of Maternal Prenatal Depression and Anxiety on Child Socio-Emotional Development. Journal of the American Academy of Child & Adolescent Psychiatry. doi: 10.1016/j.jaac.2018.06.012. 30196868 · DOI
  3. [6]Dietz PM, Williams SB, Callaghan WM, Bachman DJ, Whitlock EP, Hornbrook MC. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry. 2007; 164(10): 1515– 20. doi: 10.1176/appi.ajp.2007.06111893. 17898342 · DOI
  4. [7]Takehara K, Tachibana Y, Yoshida K, Mori R, Kakee N, Kubo T. Prevalence trends of pre- and postnatal depression in Japanese women: A population-based longitudinal study. J Affect Disord. 2018; 225: 389– 94. doi: 10.1016/j.jad.2017.08.008. 28846961 · DOI
  5. [8]Anokye R, Acheampong E, Budu-Ainooson A, Obeng EI, Akwasi AG. Prevalence of postpartum depression and interventions utilized for its management. Ann Gen Psychiatry. 2018; 17: 18. doi: 10.1186/s12991-018-0188-0. 29760762 PMC5941764 · DOI
  6. [9]Bell AF, Carter CS, Davis JM, Golding J, Adejumo O, Pyra M Childbirth and symptoms of postpartum depression and anxiety: a prospective birth cohort study. Arch Womens Ment Health. 2016; 19(2): 219– 27. doi: 10.1007/s00737-015-0555-7. 26202722 PMC4938632 · DOI
  7. [10]Franca UL, McManus ML. Frequency, trends, and antecedents of severe maternal depression after three million U.S. births. PLoS One. 2018; 13(2): e0192854. doi: 10.1371/journal.pone.0192854. 29444165 PMC5812647 · DOI
  8. [11]Shakeel N, Sletner L, Falk RS, Slinning K, Martinsen EW, Jenum AK Prevalence of postpartum depressive symptoms in a multiethnic population and the role of ethnicity and integration. J Affect Disord. 2018; 241: 49– 58. doi: 10.1016/j.jad.2018.07.056. 30096592 · DOI
  9. [12]Rasmussen MH, Strom M, Wohlfahrt J, Videbech P, Melbye M. Risk, treatment duration, and recurrence risk of postpartum affective disorder in women with no prior psychiatric history: A population-based cohort study. PLoS Med. 2017; 14(9): e1002392. doi: 10.1371/journal.pmed.1002392. 28949960 PMC5614423 · DOI
  10. [15]Hanusa BH, Scholle SH, Haskett RF, Spadaro K, Wisner KL. Screening for depression in the postpartum period: a comparison of three instruments. J Womens Health (Larchmt). 2008; 17(4): 585– 96. doi: 10.1089/jwh.2006.0248. 18345995 PMC7083208 · DOI
  11. [16]Beck CT, Gable RK. Postpartum Depression Screening Scale: development and psychometric testing. Nursing research. 2000; 49(5): 272– 82. 11009122
  12. [17]Brodey BB, Goodman SH, Baldasaro RE, Brooks-DeWeese A, Wilson ME, Brodey IS Development of the Perinatal Depression Inventory (PDI)-14 using item response theory: a comparison of the BDI-II, EPDS, PDI, and PHQ-9. Arch Womens Ment Health. 2016; 19(2): 307– 16. doi: 10.1007/s00737-015-0553-9. 26271280 PMC4799794 · DOI
  13. [19]Flynn HA, Sexton M, Ratliff S, Porter K, Zivin K. Comparative performance of the Edinburgh Postnatal Depression Scale and the Patient Health Questionnaire-9 in pregnant and postpartum women seeking psychiatric services. Psychiatry Res. 2011; 187(1–2): 130– 4. doi: 10.1016/j.psychres.2010.10.022. 21122923 · DOI
  14. [20]APA. Diagnostic and Statistical Manual o f Memtal Disorders, DSM-5. Fifth Edition ed. Washington, D C.: American Psychiatric Publishing; 2013.
  15. [21]Robertson E, Celasun N, Stewart DE. Risk factors for postpartum depression. Postpartum depression: Literature review of risk factors and interventions. Department of Mental Health and Substance Abuse: World Health Organization; 2003 p. 1– 63.
  16. [23]Sharma V, Khan M, Corpse C, Sharma P. Missed bipolarity and psychiatric comorbidity in women with postpartum depression. Bipolar Disord. 2008; 10(6): 742– 7. doi: 10.1111/j.1399-5618.2008.00606.x. 18837870 · DOI
  17. [25]Hung CI, Liu CY, Yang CH. Untreated duration predicted the severity of depression at the two-year follow-up point. PLoS One. 2017; 12(9): e0185119. doi: 10.1371/journal.pone.0185119. 28934289 PMC5608308 · DOI
  18. [26]Earls MF. Incorporating Recognition and Management of Perinatal and Postpartum Depression Into Pediatric Practice. Pediatrics. 2010; 126(5): 1032– 9. doi: peds.2010–2348 [pii] 10.1542/peds.2010-2348. 20974776 · DOI
  19. [27]ACOG. The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol. 2015; 125(5): 1268– 71. doi: 10.1097/01.AOG.0000465192.34779.dc. 25932866 · DOI
  20. [29]Dindo L, Elmore A, O’Hara M, Stuart S. The comorbidity of Axis I disorders in depressed pregnant women. Arch Womens Ment Health. 2017; 20(6): 757– 64. doi: 10.1007/s00737-017-0769-y. 28842756 PMC5759963 · DOI
  21. [31]Newport DJ, Levey LC, Pennell PB, Ragan K, Stowe ZN. Suicidal ideation in pregnancy: assessment and clinical implications. Arch Womens Ment Health. 2007; 10(5): 181– 7. doi: 10.1007/s00737-007-0192-x. 17726640 · DOI
  22. [33]Putnam K, Robertson-Blackmore E, Sharkey K, Payne J, Bergink V, Munk-Olsen T Heterogeneity of postpartum depression: a latent class analysis. Lancet Psychiatry. 2015; 2(1): 59– 67. doi: 10.1016/s2215-0366(14)00055-8. 26359613 PMC4800818 · DOI
  23. [34]Putnam KT, Wilcox M, Robertson-Blackmore E, Sharkey K, Bergink V, Munk-Olsen T Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry. 2017; 4(6): 477– 85. doi: 10.1016/S2215-0366(17)30136-0. 28476427 PMC5836292 · DOI
  24. [35]Bernstein IH, Rush AJ, Yonhers K, Carmody TJ, Woo A, McConnell K Symptom features of postpartum depression: are they distinct? Depress Anxiety. 2008; 25(1): 20– 6. doi: 10.1002/da.20276. 17187349 PMC2268615 · DOI
  25. [36]Pope CJ, Xie B, Sharma V, Campbell MK. A prospective study of thoughts of self-harm and suicidal ideation during the postpartum period in women with mood disorders. Arch Womens Ment Health. 2013; 16(6): 483– 8. doi: 10.1007/s00737-013-0370-y. 23784481 · DOI · Paper page
  26. [38]Spinelli MG. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. Am J Psychiatry. 2004; 161(9): 1548– 57. doi: 10.1176/appi.ajp.161.9.1548. 15337641 · DOI
  27. [39]Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005; 8(2): 77– 87. doi: 10.1007/s00737-005-0080-1. 15883651 · DOI · Paper page
  28. [42]Segre LS, O’Hara MW, Arndt S, Stuart S. The prevalence of postpartum depression: the relative significance of three social status indices. Soc Psychiatry Psychiatr Epidemiol. 2007; 42(4): 316– 21. doi: 10.1007/s00127-007-0168-1. 17370048 · DOI
  29. [43]Mershy JP, Janczewstì CE. Adverse Childhood Experiences and Postpartum Depression in Home Visiting Programs: Prevalence, Association, and Mediating Mechanisms. Maternal and child health journal. 2018; 22(7): 1051– 8. doi: 10.1007/s10995-018-2488-z. 29435785 · DOI
  30. [44]Homish GG, Cornelius JR, Richardson GA, Day NL. Antenatal rish factors associated with postpartum comorbid alcohol use and depressive symptomatology. Alcoholism, clinical and experimental research. 2004; 28(8): 1242– 8. 15318124
  31. [45]Hu R, Li Y, Zhang Z, Yan W. Antenatal depressive symptoms and the rish of preeclampsia or operative deliveries: a meta-analysis. PLoS One. 2015; 10(3): e0119018. doi: 10.1371/journal.pone.0119018. 25789626 PMC4366102 · DOI
  32. [47]Yedid Sion M, Harlev A, Weintraub AY, Sergienko R, Sheiner E. Is antenatal depression associated with adverse obstetric and perinatal outcomes? J Matern Fetal Neonatal Med. 2016; 29(6): 863– 7. doi: 10.3109/14767058.2015.1023708. 25777791 · DOI
  33. [48]Badr LK, Ayvazian N, Lameh S, Charafeddine L. Is the Effect of Postpartum Depression on Mother-Infant Bonding Universal? Infant Behav Dev. 2018; 51: 15– 23. doi: 10.1016/j.infbeh.2018.02.003. 29533871 · DOI · Paper page
  34. [49]Smith-Nielsen J, Tharner A, Krogh MT, Vaever MS. Effects of maternal postpartum depression in a well-resourced sample: Early concurrent and long-term effects on infant cognitive, language, and motor development. Scandinavian journal of psychology. 2016; 57(6): 571– 83. doi: 10.1111/sjop.12321. 27611177 · DOI
  35. [51]Kawai E, Takagai S, Takei N, Itoh H, Kanayama N, Tsuchiya KJ. Maternal postpartum depressive symptoms predict delay in non-verbal communication in 14-month-old infants. Infant Behav Dev. 2017; 46: 33– 45. doi: 10.1016/j.infbeh.2016.11.006. 27870989 · DOI
  36. [52]Martini J, Petzoldt J, Knappe S, Garthus-Niegel S, Asselmann E, Wittchen HU. Infant, maternal, and familial predictors and correlates of regulatory problems in early infancy: The differential role of infant temperament and maternal anxiety and depression. Early Hum Dev. 2017; 115: 23– 31. doi: 10.1016/j.earlhumdev.2017.08.005. 28869923 · DOI
  37. [53]Meiser S, Zietlow AL, Reck C, Trauble B. The impact of postpartum depression and anxiety disorders on children’s processing of facial emotional expressions at pre-school age. Arch Womens Ment Health. 2015; 18(5): 707– 16. doi: 10.1007/s00737-015-0519-y. 25833807 · DOI
  38. [54]Kersten-Alvarez LE, Hosman CM, Riksen-Walraven JM, van Doesum KT, Smeekens S, Hoefnagels C. Early school outcomes for children of postpartum depressed mothers: comparison with a community sample. Child psychiatry and human development. 2012; 43(2): 201– 18. doi: 10.1007/s10578-011-0257-y. 22011810 PMC3303034 · DOI
  39. [55]Klier CM, Rosenblum KL, Zeller M, Steinhardt K, Bergemann N, Muzik M. A multirisk approach to predicting chronicity of postpartum depression symptoms. Depress Anxiety. 2008; 25(8): 718– 24. doi: 10.1002/da.20419. 18729148 PMC3150733 · DOI
  40. [57]Letourneau NL, Tramonte L, Willms JD. Maternal depression, family functioning and children’s longitudinal development. Journal of pediatric nursing. 2013; 28(3): 223– 34. doi: 10.1016/j.pedn.2012.07.014. 22940454 · DOI
  41. [58]Kimmel MC, Cox E, Schiller C, Gettes E, Meltzer-Brody S. Pharmacologic Treatment of Perinatal Depression. Obstetrics and gynecology clinics of North America. 2018; 45(3): 419– 40. doi: 10.1016/j.ogc.2018.04.007. 30092919 · DOI
  42. [59]Roy A, Cole K, Goldman Z, Barris M. Fluoxetine treatment of postpartum depression. Am J Psychiatry. 1993; 150(8): 1273. 8328582
  43. [60]Stowe ZN, Casarella J, Landry J, Nemeroff CB. Sertraline in the treatment of women with postpartum major depression. Depression. 1995; 3(1–2): 49– 55. doi: 10.1002/depr.3050030109. · DOI
  44. [61]Suri R, Burt VK, Altshuler LL, Zuckerbrow-Miller J, Fairbanks L. Fluvoxamine for postpartum depression. Am J Psychiatry. 2001; 158(10): 1739– 40. doi: 10.1176/appi.ajp.158.10.1739. 11579021 · DOI
  45. [62]Misri S, Abizadeh J, Albert G, Carter D, Ryan D. Restoration of functionality in postpartum depressed mothers: an open-label study with escitalopram. J Clin Psychopharmacol. 2012; 32(5): 729– 32. doi: 10.1097/JCP.0b013e31826867c9. 22926619 · DOI
  46. [63]Milgrom J, Gemmili AW, Ericksen J, Burrows G, Buist A, Reece J. Treatment of postnatal depression with cognitive behavioural therapy, sertraline and combination therapy: a randomised controlled trial. Aust N Z J Psychiatry. 2015; 49(3): 236– 45. doi: 10.1177/0004867414565474. 25586754 · DOI · Paper page
  47. [64]Hantsoo L, Ward-O’Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology (Beri). 2014; 231(5): 939– 48. doi: 10.1007/s00213-013-3316-1. PMC3945214 24173623 · DOI
  48. [65]Bloch M, Meiboom H, Lorberblatt M, Bluvstein I, Aharonov I, Schreiber S. The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double­blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(2): 235– 41. doi: 10.4088/JCP.11m07117. 22401479 · DOI
  49. [66]Sharp DJ, Chew-Graham C, Tylee A, Lewis G, Howard L, Anderson I A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. Health technology assessment (Winchester, England). 2010; 14(43): iii-iv, ix-xi, 1– 153. doi: 10.3310/hta14430. 20860888 · DOI
  50. [68]Wisner KL, Hanusa BH, Perei JM, Peindl KS, Piontek CM, Sit DK Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006; 26(4): 353– 60. doi: 10.1097/01.jcp.0000227706.56870.dd. 16855451 · DOI
  51. [69]Misri S, Reebye P, Corral M, Milis L. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry. 2004; 65(9): 1236– 41. 15367052
  52. [70]Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive behavioural counselling in the treatment of postnatal depression. Bmj. 1997; 314(7085): 932– 6. 9099116 PMC2126383
  53. [74]Misri S, Swift E, Abizadeh J, Shankar R. Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing. Therapeutic advances in psychopharmacology. 2016; 6(4): 269– 76. doi: 10.1177/2045125316656297. 27536346 PMC4971603 · DOI
  54. [75]Nonacs RM, Soares CN, Viguera AC, Pearson K, Poitras JR, Cohen LS. Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol. 2005; 8(3): 445– 9. doi: 10.1017/s1461145705005079. 15817137 · DOI
  55. [76]Suri R, Burt VK, Altshuler LL. Nefazodone for the treatment of postpartum depression. Arch Womens Ment Health. 2005; 8(1): 55– 6. doi: 10.1007/s00737-005-0071-2. 15868388 · DOI
  56. [77]Marrocco J, McEwen BS. Sex in the brain: hormones and sex differences. Dialogues Clin Neurosci. 2016; 18(4): 373– 83. 28179809 PMC5286723
  57. [78]Rubinow DR, Schmidt PJ. Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology. 2018. doi: 10.1038/s41386-018-0148-z. PMC6235863 30061743 · DOI
  58. [79]Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet (London, England). 1996; 347(9006): 930– 3. 8598756
  59. [80]Wisner KL, Sit DK, Moses-Kolko EL, Driscoll KE, Prairie BA, Stika CS Transdermal Estradiol Treatment for Postpartum Depression: A Pilot, Randomized Trial. J Clin Psychopharmacol. 2015; 35(4): 389– 95. doi: 10.1097/jcp.0000000000000351. 26061609 PMC4485597 · DOI
  60. [81]Moses-Kolko EL, Berga SL, Kairo B, Sit DK, Wisner KL. Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol. 2009; 52(3): 516– 29. doi: 10.1097/GRF.0b013e3181b5a395. 19661765 PMC2782667 · DOI
  61. [82]Lawrie TA, Hofmeyr GJ, De Jager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. British journal of obstetrics and gynaecology. 1998; 105(10): 1082– 90. 9800931
  62. [83]Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. The journal of family planning and reproductive health care. 2016; 42(3): 171– 6. doi: 10.1136/jfprhc-2015-101334. 27030698 · DOI
  63. [84]Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception. 2010; 82(2): 174– 7. doi: 10.1016/j.contraception.2010.03.004. 20654759 · DOI
  64. [85]Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. The Cochrane database of systematic reviews. 2008(4): Cd001690. doi: 10.1002/14651858.CD001690.pub2. PMC7061327 18843619 · DOI
  65. [86]Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001; 62(2): 82– 6. 11247106
  66. [87]Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011; 117(4): 961– 77. doi: 10.1097/AOG.0b013e31821187a7. 21422871 · DOI
  67. [88]Wisner KL, Perei JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004; 161(7): 1290– 2. doi: 10.1176/appi.ajp.161.7.1290. 15229064 · DOI
  68. [89]Khazaie H, Ghadami MR, Knight DC, Emamian F, Tahmasian M. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. Psychiatry Res. 2013; 210(3): 901– 5. doi: 10.1016/j.psychres.2013.08.017. 23993464 · DOI
  69. [90]Molyneaux E, Telesia LA, Henshaw C, Boath E, Bradley E, Howard LM. Antidepressants for preventing postnatal depression. The Cochrane database of systematic reviews. 2018; 4: Cd004363. doi: 10.1002/14651858.CD004363.pub3. PMC6494522 29669175 · DOI
  70. [91]Walton GD, Ross LE, Stewart DE, Grigoriadis S, Dennis CL, Vigod S. Decisional conflict among women considering antidepressant medication use in pregnancy. Arch Womens Ment Health. 2014; 17(6): 493– 501. doi: 10.1007/s00737-014-0448-1. 25104244 · DOI · Paper page
  71. [93]Hall HR, Jolly K. Women’s use of complementary and alternative medicines during pregnancy: a cross-sectional study. Midwifery. 2014; 30(5): 499– 505. doi: 10.1016/j.midw.2013.06.001. 23849906 · DOI
  72. [94]Wu P, Fuller C, Liu X, Lee HC, Fan B, Hoven CW Use of complementary and alternative medicine among women with depression: results of a national survey. Psychiatr Serv. 2007; 58(3): 349– 56. doi: 10.1176/ps.2007.58.3.349. 17325108 · DOI · Paper page
  73. [95]Stuart S, Koleva H. Psychological treatments for perinatal depression. Best practice & research Clinical obstetrics & gynaecology. 2014; 28(1): 61– 70. doi: 10.1016/j.bpobgyn.2013.09.004. 24269903 · DOI
  74. [96]Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. The Cochrane database of systematic reviews. 2013(2): Cd001134. doi: 10.1002/14651858.CD001134.pub3. PMC11936315 23450532 · DOI · Paper page
  75. [97]Reza N, Deligiannidis KM, Eustis EH, Battle CL. Complementary Health Practices for Treating Perinatal Depression. Obstetrics and gynecology clinics of North America. 2018; 45(3): 441– 54. doi: 10.1016/j.ogc.2018.04.002. 30092920 · DOI
  76. [98]Rundgren S, Brus O, Bave U, Landen M, Lundberg J, Nordanskog P Improvement of postpartum depression and psychosis after electroconvulsive therapy: A population-based study with a matched comparison group. J Affect Disord. 2018; 235: 258– 64. doi: 10.1016/j.jad.2018.04.043. 29660641 · DOI
  77. [99]Ward HB, Fromson JA, Cooper JJ, De Oliveira G, Almeida M. Recommendations for the use of ECT in pregnancy: literature review and proposed clinical protocol. Arch Womens Ment Health. 2018. doi: 10.1007/s00737-018-0851-0. 29796968 · DOI
  78. [100]Myczkowski ML, Dias AM, Luvisotto T, Arnaut D, Bellini BB, Mansur CG Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression. Neuropsychiatric disease and treatment. 2012; 8: 491– 500. doi: 10.2147/ndt.s33851. 23118543 PMC3484900 · DOI
  79. [102]Andriotti T, Stavale R, Nafee T, Fakhry S, Mohamed MMA, Sofiyeva N ASSERT trial-How to assess the safety and efficacy of a high frequency rTMS in postpartum depression? A multicenter, double blinded, randomized, placebo-controlled clinical trial. Contemporary clinical trials communications. 2017; 5: 86– 91. doi: 10.1016/j.conctc.2017.01.004. 29740625 PMC5936708 · DOI
  80. [103]Vigod S, Dennis CL, Daskalakis Z, Murphy K, Ray J, Oberlander T Transcranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: study protocol for a pilot randomized controlled trial. Trials. 2014; 15: 366. doi: 10.1186/1745-6215-15-366. 25234606 PMC4177439 · DOI
  81. [104]Kim DR, Snell JL, Ewing GC, O’Reardon J. Neuromodulation and antenatal depression: a review. Neuropsychiatric disease and treatment. 2015; 11: 975– 82. doi: 10.2147/ndt.s80480. 25897234 PMC4397922 · DOI
  82. [106]Bloch M, Rubinow DR, Schmidt PJ, Lotsikas A, Chrousos GP, Cizza G. Cortisol response to ovine corticotropin-releasing hormone in a model of pregnancy and parturition in euthymic women with and without a history of postpartum depression. J Clin Endocrinol Metab. 2005; 90(2): 695– 9. doi: jc.2004–1388 [pii] 10.1210/jc.2004-1388. 15546899 · DOI
  83. [107]Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000; 157(6): 924– 30. 10831472
  84. [108]Deligiannidis KM, Sikoglu EM, Shaffer SA, Frederick B, Svenson AE, Kopoyan A GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study. J Psychiatr Res. 2013; 47(6): 816– 28. doi: 10.1016/j.jpsychires.2013.02.010. 23499388 PMC3983790 · DOI
  85. [109]Harris B, Lovett L, Newcombe RG, Read GF, Walker R, Riad-Fahmy D. Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II. BMJ. 1994; 308(6934): 949– 53. 8173402 PMC2539811
  86. [110]Magiakou MA, Mastorakos G, Rabin D, Dubbert B, Gold PW, Chrousos GP. Hypothalamic corticotropin-releasing hormone suppression during the postpartum period: implications for the increase in psychiatric manifestations at this time. J Clin Endocrinol Metab. 1996; 81(5): 1912– 7. 8626857
  87. [111]Stuebe AM, Grewen K, Pedersen CA, Propper C, Meltzer-Brody S. Failed lactation and perinatal depression: common problems with shared neuroendocrine mechanisms? J Womens Health (Larchmt). 2012; 21(3): 264– 72. doi: 10.1089/jwh.2011.3083. 22204416 PMC3298672 · DOI
  88. [112]Hellgren C, Akerud H, Skalkidou A, Sundstrom-Poromaa I. Cortisol awakening response in late pregnancy in women with previous or ongoing depression. Psychoneuroendocrinology. 2013; 38(12): 3150– 4. doi: 10.1016/j.psyneuen.2013.08.007. 24041544 · DOI
  89. [113]Meinlschmidt G, Martin C, Neumann ID, Heinrichs M. Maternal cortisol in late pregnancy and hypothalamic-pituitary-adrenal reactivity to psychosocial stress postpartum in women. Stress. 2010; 13(2): 163– 71. doi: 10.3109/10253890903128632. 20214437 · DOI
  90. [114]Nierop A, Bratsikas A, Zimmermann R, Ehlert U. Are stress-induced cortisol changes during pregnancy associated with postpartum depressive symptoms? Psychosom Med. 2006; 68(6): 931– 7. doi: 68/6/931 [pii] 10.1097/01.psy.0000244385.93141.3b. 17132840 · DOI
  91. [115]Corwin EJ, Pajer K, Paul S, Lowe N, Weber M, McCarthy DO. Bidirectional psychoneuroimmune interactions in the early postpartum period influence risk of postpartum depression. Brain, behavior, and immunity. 2015; 49: 86– 93. doi: 10.1016/j.bbi.2015.04.012. PMC4567438 25937051 · DOI
  92. [116]Boufidou F, Lambrinoudaki I, Argeitis J, Zervas IM, Pliatsika P, Leonardou AA CSF and plasma cytokines at delivery and postpartum mood disturbances. J Affect Disord. 2009; 115(1–2): 287– 92. doi: 10.1016/j.jad.2008.07.008. 18708264 · DOI
  93. [117]Sharkey KM, Pearlstein TB, Carskadon MA. Circadian phase shifts and mood across the perinatal period in women with a history of major depressive disorder: a preliminary communication. J Affect Disord. 2013; 150(3): 1103– 8. doi: 10.1016/j.jad.2013.04.046. 23706877 PMC3759598 · DOI
  94. [118]Parry BL, Meliska CJ, Sorenson DL, Lopez AM, Martinez LF, Nowakowski S Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression. Am J Psychiatry. 2008; 165(12): 1551– 8. doi: 10.1176/appi.ajp.2008.08050709. 18829869 PMC3038788 · DOI
  95. [119]Costas J, Gratacos M, Escaramis G, Martin-Santos R, de Diego Y, Baca-Garcia E Association study of 44 candidate genes with depressive and anxiety symptoms in post-partum women. J Psychiatr Res. 2010; 44(11): 717– 24. doi: 10.1016/j.jpsychires.2009.12.012. 20092830 · DOI
  96. [120]Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry. 2014; 19(5): 560– 7. doi: 10.1038/mp.2013.62. 23689534 PMC7039252 · DOI
  97. [121]Deligiannidis KM, Fales CL, Kroll-Desrosiers AR, Shaffer SA, Villamarin V, Tan Y Intrinsic resting-state functional connectivity, cortical γ-aminobutyric acid and peripheral neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic imaging and resonance study.. Accepted, in press, Neuropsychopharmacology and available at BioRxiv 411405. 2018. doi: Available from: https://doi.org/10/1101/411405. PMC6333815 30327498
  98. [122]Silver M, Moore CM, Villamarin V, Jaitly N, Hall JE, Rothschild AJ White matter integrity in medication-free women with peripartum depression: a tract-based spatial statistics study. Neuropsychopharmacology. 2018; 43(7): 1573– 80. doi: 10.1038/s41386-018-0023-y. 29453442 PMC5983547 · DOI
  99. [123]B lacttum ST. Reproductive and developmental processes In: Jachson C, editor. Maternal, Fetal and Neonatal Physiology. Philadelphia, PA, USA: Elsevier Health Sciences; 2007 p. 100– 2.
  100. [125]Bammann BL, Coulam CB, Jiang NS. Total and free testosterone during pregnancy. American journal of obstetrics and gynecology. 1980; 137(3): 293– 8. 7189643
  101. [127]Hill M, Parizeh A, Klak J, Hampl R, Sulcova J, Havlihova H Neuroactive steroids, their precursors and polar conjugates during parturition and postpartum in maternal and umbilical blood: 3.3beta-hydroxy-5-ene steroids. J Steroid Biochem Mol Biol. 2002; 82(2–3): 241– 50. 12477491
  102. [128]Hill M, Cibula D, Havlihova H, Kancheva L, Fait T, Kancheva R Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. J Steroid Biochem Mol Biol. 2007; 105(1–5): 166– 75. doi: 10.1016/j.jsbmb.2006.10.010. 17583491 · DOI
  103. [129]Deligiannidis KM, Kroll-Desrosiers AR, Svenson A, Jaitly N, Barton BA, Hall JE Cortisol response to the Trier Social Stress Test in pregnant women at rish for postpartum depression. Arch Womens Ment Health. 2016; 19(5): 789– 97. doi: 10.1007/s00737-016-0615-7. 26951216 PMC5014732 · DOI
  104. [130]Halligan SL, Herbert J, Goodyer I, Murray L. Disturbances in morning cortisol secretion in association with maternal postnatal depression predict subsequent depressive symptomatology in adolescents. Biol Psychiatry. 2007; 62(1): 40– 6. doi: 10.1016/j.biopsych.2006.09.011. 17188253 · DOI · Paper page
  105. [131]Nierop A, Bratsihas A, Klinhenberg A, Nater UM, Zimmermann R, Ehlert U. Prolonged salivary cortisol recovery in second-trimester pregnant women and attenuated salivary alpha-amylase responses to psychosocial stress in human pregnancy. J Clin Endocrinol Metab. 2006; 91(4): 1329– 35. doi: jc.2005–1816 [pii] 10.1210/jc.2005-1816. 16434458 · DOI
  106. [132]O’Connor TG, Tang W, Gilchrist MA, Moynihan JA, Pressman EK, Blackmore ER. Diurnal cortisol patterns and psychiatric symptoms in pregnancy: short-term longitudinal study. Biological psychology. 2014; 96: 35– 41. doi: 10.1016/j.biopsycho.2013.11.002. 24239618 PMC5788168 · DOI
  107. [133]Meltzer-Brody S, Stuebe A, Dole N, Savitz D, Rubinow D, Thorp J. Elevated corticotropin releasing hormone (CRH) during pregnancy and risk of postpartum depression (PPD). J Clin Endocrinol Metab. 2011; 96(1): E40– 7. doi: 10.1210/jc.2010-0978. 20943787 PMC3038484 · DOI
  108. [134]Zaconeta AM, Amato AA, Barra GB, Casulari da Motta LD, de Souza VC, Karnikowski MG Cerebrospinal Fluid CRH Levels in Late Pregnancy Are Not Associated With New-Onset Postpartum Depressive Symptoms. J Clin Endocrinol Metab. 2015; 100(8): 3159– 64. doi: 10.1210/jc.2014-4503. 26066672 · DOI
  109. [135]Glynn LM, Sandman CA. Evaluation of the association between placental corticotrophin-releasing hormone and postpartum depressive symptoms. Psychosom Med. 2014; 76(5): 355– 62. doi: 10.1097/psy.0000000000000066. 24915294 · DOI
  110. [136]Yim IS, Glynn LM, Dunkel-Schetter C, Hobel CJ, Chicz-DeMet A, Sandman CA. Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy. Arch Gen Psychiatry. 2009; 66(2): 162– 9. doi: 10.1001/archgenpsychiatry.2008.533. 19188538 PMC2768579 · DOI
  111. [137]Ferguson EH, Di Florio A, Pearson B, Putnam KT, Girdler S, Rubinow DR HPA axis reactivity to pharmacologic and psychological stressors in euthymic women with histories of postpartum versus major depression. Arch Womens Ment Health. 2017; 20(3): 411– 20. doi: 10.1007/s00737-017-0716-y. 28251369 PMC5441453 · DOI
  112. [138]Crowley SK, O’Buckley TK, Schiller CE, Stuebe A, Morrow AL, Girdler SS. Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Beri). 2016; 233(7): 1299– 310. doi: 10.1007/s00213-0164217-x. PMC4803569 26856852 · DOI
  113. [139]Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011; 36(9): 1886– 93. doi: 10.1038/npp.2011.74. 21562482 PMC3154107 · DOI · Paper page
  114. [140]King L, Robins S, Chen G, Yerko V, Zhou Y, Nagy C Perinatal depression and DNA methylation of oxytocin-related genes: a study of mothers and their children. Horm Behav. 2017; 96: 84– 94. doi: 10.1016/j.yhbeh.2017.09.006. 28918249 · DOI
  115. [141]Kroll-Desrosiers AR, Nephew BC, Babb JA, Guilarte-Walker Y, Moore Simas TA, Deligiannidis KM. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depress Anxiety. 2017; 34(2): 137– 46. doi: 10.1002/da.22599. 28133901 PMC5310833 · DOI
  116. [142]Okun ML, Luther J, Prather AA, Perel JM, Wisniewski S, Wisner KL. Changes in sleep quality, but not hormones predict time to postpartum depression recurrence. J Affect Disord. 2011; 130(3): 378– 84. doi: 10.1016/j.jad.2010.07.015. 20708275 PMC3006083 · DOI · Paper page
  117. [143]O’Hara MW, Schlechte JA, Lewis DA, Wright EJ. Prospective study of postpartum blues. Biologic and psychosocial factors. Arch Gen Psychiatry. 1991; 48(9): 801– 6. 1929770
  118. [144]Parizek A, Mikesova M, Jirak R, Hill M, Koucky M, Paskova A Steroid hormones in the development of postpartum depression. Physiological research / Academia Scientiarum Bohemoslovaca. 2014; 63 Suppl 2: S277– 82. 24908233
  119. [145]Hohlagschwandtner M, Husslein P, Klier C, Ulm B. Correlation between serum testosterone levels and peripartal mood states. Acta obstetricia et gynecologica Scandinavica. 2001; 80(4): 326– 30. 11264607
  120. [146]Aswathi A, Rajendiren S, Nimesh A, Philip RR, Kattimani S, Jayalakshmi D High serum testosterone levels during postpartum period are associated with postpartum depression. Asian journal of psychiatry. 2015; 17: 85– 8. doi: 10.1016/j.ajp.2015.08.008. 26372084 · DOI
  121. [147]Deligiannidis KM, Kroll-Desrosiers AR, Mo S, Nguyen HP, Svenson A, Jaitly N Peripartum neuroactive steroid and gamma-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinology. 2016; 70: 98– 107. doi: 10.1016/j.psyneuen.2016.05.010. 27209438 PMC4907817 · DOI
  122. [148]Groer MW, Vaughan JH. Positive thyroid peroxidase antibody titer is associated with dysphoric moods during pregnancy and postpartum. Journal of obstetric, gynecologic, and neonatal nursing: JOGNN / NAACOG. 2013; 42(1): E26– 32. doi: 10.1111/j.1552-6909.2012.01425.x. PMC3546200 23167615 · DOI
  123. [149]Albacar G, Sans T, Martin-Santos R, Garcia-Esteve L, Guillamat R, Sanjuan J Thyroid function 48h after delivery as a marker for subsequent postpartum depression. Psychoneuroendocrinology. 2010; 35(5): 738– 42. doi: 10.1016/j.psyneuen.2009.10.015. 19939574 · DOI
  124. [150]Pedersen CA, Johnson JL, Silva S, Bunevicius R, Meltzer-Brody S, Hamer RM Antenatal thyroid correlates of postpartum depression. Psychoneuroendocrinology. 2007; 32(3): 235– 45. doi: 10.1016/j.psyneuen.2006.12.010. 17346901 · DOI
  125. [151]Sylven SM, Elenis E, Michelakos T, Larsson A, Olovsson M, Poromaa IS Thyroid function tests at delivery and risk for postpartum depressive symptoms. Psychoneuroendocrinology. 2013; 38(7): 1007– 13. doi: 10.1016/j.psyneuen.2012.10.004. 23137714 · DOI
  126. [152]Sandman CA, Glynn LM. Corticotropin-Releasing Hormone (CRH) Programs the Fetal and Maternal Brain. Future Neurol. 2009; 4(3): 257– 61. 19680459 PMC2725328
  127. [153]Duthie L, Reynolds RM. Changes in the maternal hypothalamic-pituitary-adrenal axis in pregnancy and postpartum: influences on maternal and fetal outcomes. Neuroendocrinology. 2013; 98(2): 106– 15. doi: 10.1159/000354702. 23969897 · DOI
  128. [154]McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R. A placental clock controlling the length of human pregnancy. Nat Med. 1995; 1(5): 460– 3. 7585095
  129. [155]Sandman CA, Glynn L, Schetter CD, Wadhwa P, Garite T, Chicz-DeMet A Elevated maternal cortisol early in pregnancy predicts third trimester levels of placental corticotropin releasing hormone (CRH): priming the placental clock. Peptides. 2006; 27(6): 1457– 63. doi: 10.1016/j.peptides.2005.10.002. 16309788 · DOI · Paper page
  130. [156]Sasaki A, Liotta AS, Luckey MM, Margioris AN, Suda T, Krieger DT. Immunoreactive corticotropin-releasing factor is present in human maternal plasma during the third trimester of pregnancy. J Clin Endocrinol Metab. 1984; 59(4): 812– 4. doi: 10.1210/jcem-59-4-812. 6332823 · DOI
  131. [157]Mastorakos G, Ilias I. Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci. 2003; 997: 136– 49. 14644820
  132. [158]Nolten WE, Lindheimer MD, Rueckert PA, Oparil S, Ehrlich EN. Diurnal patterns and regulation of cortisol secretion in pregnancy. J Clin Endocrinol Metab. 1980; 51(3): 466– 72. 7410530
  133. [159]Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011; 96(5): 1533– 40. doi: 10.1210/jc.2010-2395. 21367926 · DOI · Paper page
  134. [160]O’Keane V, Lightman S, Patrick K, Marsh M, Papadopoulos AS, Pawlby S Changes in the maternal hypothalamic-pituitary-adrenal axis during the early puerperium may be related to the postpartum ‘blues’. Journal of neuroendocrinology. 2011; 23(11): 1149– 55. doi: 10.1111/j.13652826.2011.02139.x. 22004568 · DOI
  135. [161]Buss C, Entringer S, Reyes JF, Chicz-DeMet A, Sandman CA, Waffarn F The maternal cortisol awakening response in human pregnancy is associated with the length of gestation. American journal of obstetrics and gynecology. 2009; 201(4): 398 e1– 8. doi: 10.1016/j.ajog.2009.06.063. 19716542 · DOI
  136. [162]Entringer S, Buss C, Shirtcliff EA, Cammack AL, Yim IS, Chicz-DeMet A Attenuation of maternal psychophysiological stress responses and the maternal cortisol awakening response over the course of human pregnancy. Stress. 2010; 13(3): 258– 68. doi: 10.3109/10253890903349501. 20067400 PMC2862645 · DOI
  137. [163]Schulte HM, Weisner D, Allolio B. The corticotrophin releasing hormone test in late pregnancy: lack of adrenocorticotrophin and cortisol response. Clinical endocrinology. 1990; 33(1): 99– 106. 2169361
  138. [164]de Weerth C, Buitelaar JK. Physiological stress reactivity in human pregnancy--a review. Neuroscience and biobehavioral reviews. 2005; 29(2): 295– 312. doi: 10.1016/j.neubiorev.2004.10.005. 15811500 · DOI
  139. [165]Giesbrecht GF, Campbell T, Letourneau N, Kaplan BJ. Advancing gestation does not attenuate biobehavioural coherence between psychological distress and cortisol. Biological psychology. 2013; 93(1): 45– 51. doi: 10.1016/j.biopsycho.2013.01.019. 23410761 · DOI
  140. [167]Butterfield MI, Stechuchak KM, Connor KM, Davidson JR, Wang C, MacKuen CL Neuroactive steroids and suicidality in posttraumatic stress disorder. Am J Psychiatry. 2005; 162(2): 380– 2. doi: 10.1176/appi.ajp.162.2.380. 15677605 · DOI · Paper page
  141. [168]Lopez-Rodriguez AB, Acaz-Fonseca E, Giatti S, Caruso D, Viveros MP, Melcangi RC Correlation of brain levels of progesterone and dehydroepiandrosterone with neurological recovery after traumatic brain injury in female mice. Psychoneuroendocrinology. 2015; 56: 1– 11. doi: 10.1016/j.psyneuen.2015.02.018. 25770855 · DOI
  142. [169]Guille C, Spencer S, Cavus I, Epperson CN. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment. Epilepsy & behavior: E&B. 2008; 13(1): 12– 24. doi: 10.1016/j.yebeh.2008.02.004. PMC4112568 18346939 · DOI
  143. [170]Backstrom T, Haage D, Lofgren M, Johansson IM, Stromberg J, Nyberg S Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011; 191: 46– 54. doi: 10.1016/j.neuroscience.2011.03.061. 21600269 · DOI · Paper page
  144. [171]Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Morales RR, Frajese GV Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer’s disease. Neurobiol Aging. 2011; 32(11): 1964– 76. doi: 10.1016/j.neurobiolaging.2009.12.014. 20045216 · DOI
  145. [172]Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2014: 1– 12. doi: 10.1017/s1092852914000480. PMC4363269 25263255 · DOI
  146. [173]Schiller CE, Schmidt PJ, Rubinow DR. Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology (Beri). 2014; 231(17): 3557– 67. doi: 10.1007/s00213014-3599-x. PMC4135022 24846476 · DOI
  147. [174]Paul SM, Purdy RH. Neuroactive steroids. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 1992; 6(6): 2311– 22. 1347506
  148. [175]Baulieu EE. Steroid hormones in the brain: several mechanisms? In: Fuxe F, Gustaffson JA, Wetterberg L, editors. Steroid Hormone Regulation of the Brain. Oxford, UK: Pergamon Press; 1981 p. 3– 14.
  149. [177]Avoli M, Krnjevic K. The Long and Winding Road to Gamma-Amino-Butyric Acid as Neurotransmitter. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques. 2016; 43(2): 219– 26. doi: 10.1017/cjn.2015.333. 26763167 · DOI
  150. [178]Callachan H, Cottrell GA, Hather NY, Lambert JJ, Nooney JM, Peters JA. Modulation of the GABAA receptor by progesterone metabolites. Proceedings of the Royal Society of London Series B, Biological sciences. 1987; 231(1264): 359– 69. 2888123
  151. [179]Lambert JJ, Peters JA, Sturgess NC, Hales TG. Steroid modulation of the GABAA receptor complex: electrophysiological studies. Ciba Foundation symposium. 1990; 153: 56– 71; discussion −82. 1963400
  152. [180]Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2008; 60(3): 243– 60. doi: 10.1124/pr.108.00505. 18790874 PMC2847512 · DOI · Paper page
  153. [181]Semyanov A, Walker MC, Kullmann DM. GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat Neurosci. 2003; 6(5): 484– 90. doi: 10.1038/nn1043. 12679782 · DOI
  154. [182]Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A. 2003; 100(24): 14439– 44. doi: 10.1073/pnas.2435457100 2435457100 [pii]. 14623958 PMC283610 · DOI
  155. [183]Parizek A, Hill M, Kancheva R, Havlikova H, Kancheva L, Cindr J Neuroactive pregnanolone isomers during pregnancy. J Clin Endocrinol Metab. 2005; 90(1): 395– 403. doi: 10.1210/jc.2004-0444. 15486056 · DOI
  156. [184]Mostallino MC, Sanna E, Concas A, Biggio G, Follesa P. Plasticity and function of extrasynaptic GABA(A) receptors during pregnancy and after delivery. Psychoneuroendocrinology. 2009. doi: S03064530(09)00203–0 [pii] 10.1016/j.psyneuen.2009.06.013. 19608348 · DOI · Paper page
  157. [185]Zhao C, Gammie SC. Glutamate, GABA, and glutamine are synchronously upregulated in the mouse lateral septum during the postpartum period. Brain Res. 2014; 1591: 53– 62. doi: 10.1016/j.brainres.2014.10.023. 25451092 PMC4312212 · DOI
  158. [186]Smolen A, Smolen TN, Han PC. Alterations in regional brain GABA concentration and turnover during pregnancy. Pharmacol Biochem Behav. 1993; 44(1): 63– 9. 8430130
  159. [187]Maguire J, Mody I. Steroid hormone fluctuations and GABA(A)R plasticity. Psychoneuroendocrinology. 2009; 34 Suppl 1: S84– 90. doi: 10.1016/j.psyneuen.2009.06.019. 19632051 PMC3399241 · DOI
  160. [188]Maguire J, Ferando I, Simonsen C, Mody I. Excitability changes related to GABAA receptor plasticity during pregnancy. J Neurosci. 2009; 29(30): 9592– 601. doi: 10.1523/JNEUROSCI.2162-09.2009. 19641122 PMC2875247 · DOI
  161. [189]Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008; 59(2): 207– 13. doi: S0896–6273(08)00537–0 [pii] 10.1016/j.neuron.2008.06.019. 18667149 PMC2875248 · DOI · Paper page
  162. [190]Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Beri). 2006; 186(3): 425– 33. doi: 10.1007/s00213-006-0313-7. 16724188 · DOI
  163. [193]Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988; 45(8): 742– 7. 3395203
  164. [195]Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2002; 59(9): 851– 8. 12215085
  165. [196]Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002; 159(4): 663– 5. 11925309
  166. [197]Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004; 61(7): 705– 13. doi: 10.1001/archpsyc.61.7.705. 15237082 · DOI
  167. [199]Gabbay V, Bradley KA, Mao X, Ostrover R, Kang G, Shungu DC. Anterior cingulate cortex gamma-aminobutyric acid deficits in youth with depression. Translational psychiatry. 2017; 7(8): e1216. doi: 10.1038/tp.2017.187. 28892070 PMC5611750 · DOI
  168. [200]van BroeRhoven F, Bächström T, van Luijtelaar G, Buitelaar JK, Smits P, VeAes RJ. Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology. 2007; 32(5): 555– 64. doi: 10.1016/j.psyneuen.2007.03.009. 17470385 · DOI
  169. [201]Timby E, Balgard M, Nyberg S, Spigset O, Andersson A, PoranHewicz-Asplund J PharmacoHnetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Beri). 2006; 186(3): 414– 24. doi: 10.1007/s00213-005-0148-7. 16177884 · DOI
  170. [202]Kash K, Bächström T, Nilsson L-G, Sundström-Poromaa I. Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology. 2008; 199(2): 161. doi: 10.1007/s00213-008-1150-7. 18551282 · DOI
  171. [203]Kash K, Bachstrom T, Lundgren P, Sundstrom Poromaa I. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol Biochem Behav. 2009; 92(4): 608– 13. doi: 10.1016/j.pbb.2009.02.014. 19268499 · DOI
  172. [204]Timby E, Hedstrom H, Bachstrom T, Sundstrom-Poromaa I, Nyberg S, Bixo M. Allopregnanolone, a GABAA receptor agonist, decreases gonadotropin levels in women. A preliminary study. Gynecol Endocrinol. 2011; 27(12): 1087– 93. doi: 10.3109/09513590.2010.540603. 21190418 · DOI
  173. [205]Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015; 111: 85– 141. doi: 10.1016/j.eplepsyres.2015.01.001. 25769377 · DOI
  174. [208]Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab. 2000; 85(7): 2429– 33. doi: 10.1210/jcem.85.7.6675. 10902789 · DOI · Paper page
  175. [211]Therapeutics S Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection. Cambridge, MA 2018.
  176. [212]Newton ER, Hale TW. Drugs in Breast Milk. Clin Obstet Gynecol. 2015; 58(4): 868– 84. doi: 10.1097/grf.0000000000000142. 26457856 · DOI
  177. [213]Martinez Botella G, Salituro FG, Harrison BL, Beresis RT, Bai Z, Blanco MJ Neuroactive Steroids. 2. 3alpha-Hydroxy-3beta-methyl-21-(4-cyano-lH-pyrazol-1’-yl)-19-nor-5beta-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (gamma-Aminobutyric Acid)A Receptor. J Med Chem. 2017; 60(18): 7810– 9. doi: 10.1021/acs.jmedchem.7b00846. 28753313 · DOI · Paper page
  178. [214]Therapeutics S Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression, Cambridge, MA 2019 https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-sage-217-meets-primary-and-secondary. Accessed January 7, 2019 2019.
  179. [216]Osborne LM, Hermann A, Burt V, Driscoll K, Fitelson E, Meltzer-Brody S Reproductive Psychiatry: The Gap Between Clinical Need and Education. Am J Psychiatry. 2015; 172(10): 946– 8. doi: 10.1176/appi.ajp.2015.15060837. 26423479 · DOI
  180. [217]Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, Hosseinian M Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry. 2017; 50(2): 64– 8. doi: 10.1055/s-0042-115306. 27595298 · DOI
  181. [218]Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology. 2011; 22(6): 848– 54. doi: 10.1097/EDE.0b013e3182306847. 21900825 PMC3188383 · DOI
  182. [219]Xu Y, Li Y, Huang X, Chen D, She B, Ma D. Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial. Archives of gynecology and obstetrics. 2017; 295(5): 1167– 74. doi: 10.1007/s00404-017-4334-8. 28357557 · DOI

Cited by

Sorted by citations

Authors
Frieder, A., Fersh, M., Hainline, R., & Deligiannidis, K. M.
Affiliations
  • Northwell Health (US)
  • Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
Corresponding author
Deligiannidis, Kristina M.
ORCID
Deligiannidis, Kristina M.
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2019-02-21
Volume
33
Issue
3
Pages
265-282
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
DOI
10.1007/s40263-019-00605-7
PMC
PMC6424603
OpenAlex
W2916664976
Cited by
156
References
34
Citations by year
2026: 18 · 2025: 21 · 2024: 31 · 2023: 25 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 1
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (5K23MH097794)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy-related medical research
Keywords
postpartum depression, pharmacotherapy, antidepressants, brexanolone, allopregnanolone, ganaxolone, neurosteroids, GABA, new drug development, maternal and child outcomes
MeSH terms
Drug Development, Neurosteroids, Animals, Drug Combinations, Female, Humans, Pregnanes, Pregnanolone, Pyrazoles, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, GABA Modulators, Depression, Postpartum, beta-Cyclodextrins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review